Medical Access and Reimbursement in Czechia

Czechia permits therapeutic psilocybin from 1 January 2026 only inside a narrow medical framework: qualified specialist physicians, defined mental-health indications, oral individually prepared medicine, dose limits and special supervision. NUDZ stated in March 2026 that treatment had not yet started and no waiting list was open. # #

MDMA remains a controlled psychotropic substance. No routine Czech medical access or reimbursement route was identified in reviewed sources; lawful use would depend on authorised research. #

Spravato is EU-authorised for treatment-resistant major depression under supervised clinical administration. Czech public service evidence shows reimbursement from public health insurance from 1 February 2025 when criteria are met, including supervised application in a clinical setting. # #

Ketamine remains an off-label psychiatric option in Czechia. Psyon states that ketamine-assisted therapy in mental-health indications is off-label and describes partial insurer coverage for some clients, but this is organisation-level evidence rather than a national reimbursement standard. #

DMT remains controlled. No authorised routine medical access or public reimbursement route was identified; any lawful use would require approved research or another formal authorisation. #

NUDZ project materials reference 5-MeO-DMT research planning linked to dementia, but reviewed sources did not show a live Czech patient-access or reimbursement route. # #

No Czech authorised treatment or reimbursement route for ibogaine was identified in reviewed sources. Patient access should not be inferred from the broader psilocybin framework. # #

No Czech authorised medical or reimbursement route for ayahuasca was identified. DMT-related controls remain relevant, and the 2026 therapeutic framework is specific to psilocybin. # #

Mescaline remains controlled. No authorised Czech patient-access or reimbursement route was identified outside approved research. #

2C-family substances remain a controlled-substance issue rather than a medical-access pathway. No Czech treatment or reimbursement route was identified in reviewed sources. #